14 years of historical data (2011–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Arcturus Therapeutics Holdings Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $224M | $458M | $840M | $459M | $974M | $881M | $131M | $46M | $25M | $58M | $136M |
| Enterprise Value | $16M | $250M | $578M | $162M | $673M | $439M | $81M | $19M | $-423350 | $56M | $119M |
| P/E Ratio → | -2.74 | — | — | 48.46 | — | — | — | — | — | — | — |
| P/S Ratio | 1.62 | 3.31 | 5.32 | 2.23 | 78.81 | 92.34 | 6.31 | 2.90 | 1.89 | 2.84 | 22.14 |
| P/B Ratio | 0.92 | 1.90 | 3.01 | 1.70 | 4.27 | 2.22 | 5.09 | 3.34 | 0.73 | 1.23 | 1.96 |
| P/FCF | — | — | — | 18.94 | — | — | — | — | — | — | — |
| P/OCF | — | — | — | 14.36 | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.80 | 3.66 | 0.79 | 54.43 | 45.99 | 3.87 | 1.19 | -0.03 | 2.73 | 19.42 |
| EV / EBITDA | — | — | — | 11.85 | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | 13.33 | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | 6.69 | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Arcturus Therapeutics Holdings Inc. earns an operating margin of -69.1%. Operating margins have compressed from 5.9% to -69.1% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -31.2% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -486.5% | 100.0% | -7.8% | 96.8% | 98.6% | 99.2% |
| Operating Margin | -69.1% | -69.1% | -49.6% | 5.9% | -1641.3% | -749.8% | -122.7% | -138.5% | -80.7% | -123.5% | -320.9% |
| Net Profit Margin | -58.5% | -58.5% | -18.8% | 4.5% | -1648.0% | -756.3% | -125.0% | -138.3% | -83.9% | -120.7% | -316.9% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -31.2% | -31.2% | -10.8% | 3.8% | -65.2% | -34.2% | -131.8% | -91.9% | -26.9% | -42.2% | -43.6% |
| ROA | -20.9% | -20.9% | -6.8% | 2.2% | -46.9% | -25.8% | -41.1% | -45.3% | -21.0% | -39.9% | -41.4% |
| ROIC | -291.5% | -291.5% | -350.7% | — | — | — | — | — | -29.2% | -38.6% | -41.9% |
| ROCE | -30.6% | -30.6% | -23.3% | 3.9% | -56.3% | -29.3% | -55.2% | -60.1% | -23.8% | -43.2% | -44.1% |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $237M exceeds total debt of $29M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.12 | 0.12 | 0.11 | 0.35 | 0.30 | 0.05 | 0.80 | 0.73 | — | 0.00 | — |
| Debt / EBITDA | — | — | — | 6.91 | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.87 | -0.94 | -1.10 | -1.32 | -1.11 | -1.96 | -1.96 | -0.74 | -0.05 | -0.24 |
| Net Debt / EBITDA | — | — | — | -21.68 | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | -12.24 | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -101.96 | 4.06 | -75.86 | -86.07 | -29.87 | -117.26 | -69.95 | -85.31 | -78.48 |
Net cash position: cash ($237M) exceeds total debt ($29M)
Short-term solvency ratios and asset-utilisation metrics
Arcturus Therapeutics Holdings Inc.'s current ratio of 4.67x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 3.18x to 4.67x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.67 | 4.67 | 4.72 | 3.18 | 3.81 | 9.45 | 3.48 | 3.33 | 4.61 | 11.82 | 22.26 |
| Quick Ratio | 4.67 | 4.67 | 4.72 | 3.18 | 3.81 | 9.45 | 3.48 | 3.33 | 4.48 | 11.94 | 22.31 |
| Cash Ratio | 3.62 | 3.62 | 3.56 | 3.09 | 3.72 | 9.35 | 3.35 | 2.92 | 4.40 | 11.58 | 21.55 |
| Asset Turnover | — | 0.40 | 0.37 | 0.46 | 0.03 | 0.02 | 0.25 | 0.36 | 0.25 | 0.40 | 0.09 |
| Inventory Turnover | 0.28 | — | — | — | — | — | — | — | 0.28 | — | — |
| Days Sales Outstanding | — | 10.48 | 74.19 | 4.90 | 99.44 | 81.31 | 38.26 | 103.83 | 13.48 | 65.06 | 19.50 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Arcturus Therapeutics Holdings Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | 2.1% | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | 5.3% | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $27M | $27M | $27M | $26M | $20M | $12M | $10M | $3M | $4M | $3M |
Compare ARCT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| ARCTYou | $224M | -2.7 | — | — | 100.0% | -69.1% | -31.2% | -291.5% | — |
| ALNY | $44B | 142.9 | 81.4 | 94.7 | 81.8% | 13.5% | 73.3% | 19.1% | 5.3 |
| IONS | $13B | -34.1 | — | — | 98.3% | -40.5% | -70.7% | -12.2% | — |
| ARWR | $9B | -5186.1 | 76.1 | 55.4 | 97.1% | 11.9% | -0.5% | 7.2% | 6.9 |
| CRSP | $6B | -9.3 | — | — | -2642.3% | -18933.6% | -30.2% | -27.4% | — |
| BEAM | $3B | -35.1 | — | — | 84.0% | -274.6% | -8.1% | -33.6% | — |
| WVE | $2B | -19.9 | — | — | 100.0% | -101.9% | -77.9% | — | — |
| RNA | $2B | -3.0 | — | — | 77.9% | -3977.3% | -44.0% | -42.8% | — |
| STOK | $2B | -22.1 | — | — | 100.0% | -277.3% | -45.8% | -206.8% | — |
| NTLA | $2B | -3.6 | — | — | — | — | -53.5% | — | — |
| ABUS | $895M | -12.3 | — | — | 100.0% | -1236.7% | -68.8% | -75.9% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 14 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how ARCT stacks up against sector leader Alnylam Pharmaceuticals, Inc..
Start ComparisonArcturus Therapeutics Holdings Inc.'s current P/E ratio is -2.7x. The historical average is 48.5x.
Arcturus Therapeutics Holdings Inc.'s return on equity (ROE) is -31.2%. The historical average is -77.9%.
Based on historical data, Arcturus Therapeutics Holdings Inc. is trading at a P/E of -2.7x. Compare with industry peers and growth rates for a complete picture.
Arcturus Therapeutics Holdings Inc. has 100.0% gross margin and -69.1% operating margin.